[Aspirin for primary prevention of cardiovascular diseases in diabetic patients: focus on gender difference and insulin resistance].
Acetylsalicylic acid (aspirin) is widely used as antiplatelet therapy for the primary and secondary prevention of cardiovascular diseases. However, the effects appear to be different according to the studied population, with a reduction of coronary events in men and, rather, a diminution of strokes in women. Diabetes mellitus markedly increases the risk of cardiovascular diseases, with an especially elevated relative risk among women. We present a detailed analysis of the literature about the efficacy of aspirin in the primary prevention of cardiovascular complications in the diabetic population. Limited available data suggest a lower protection in the diabetic than in the non-diabetic population. A greater aspirin resistance has been suggested in diabetic patents, which might lead to the use of a higher daily dosage of aspirin in diabetic than in non diabetic patients. Whatsoever, aspirin remains the first antiplatelet agent in the diabetic population in all international guidelines of cardiovascular prevention.
Legrand
D A
DA
Université de Liège, Belgique.
Scheen
A J
AJ
D001241:Aspirin / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000378:metabolism* / Q000517:prevention & control*; D048909:Diabetes Complications / Q000378:metabolism* / Q000517:prevention & control*; D005260:Female; D006801:Humans; D007333:Insulin Resistance; D008297:Male; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D012737:Sex Factors
D010975:Platelet Aggregation Inhibitors; D001241:Aspirin